Frontage soars 49% on privatization offer at 59% premium

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Frontage (1521.HK) soared nearly 49% in Hong Kong trading to a 52-week high, last at HK$2.22.

The life sciences tools and services industry index rose 4.4% over the same period.

The stock resumed trading after a consortium led by Tigermed and named SanRex proposed a privatization offer at HK$2.37 per share, representing a premium of about 59.1%. Upon completion, the company will be delisted via a scheme of arrangement, with shareholders receiving a cancellation price plus a contingent payment based on proceeds.

Frontage will also be split as part of the transaction. Its bioanalysis and DMPK businesses will be sold to Charles River Laboratories (CRL), overseas non-target businesses will be acquired by Chairman Li Song, and domestic non-target businesses will be retained by Tigermed.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.